Abstract
than 35 mg/dL had 8-fold higher incidence of CVD compared with those with HDL-C levels of more than 65 mg/dL 11. An analysis of data from large trails demonstrated that each increase of 1 mg per deciliter in HDL-C is associated with a decrease of 2 to 3% in the risk of future coronary heart disease 12.
Anti-atherosclerotic effects of HDL
HDL-C have several physiological properties that may explain their anti-atherosclerotic effects; the best well-known is the ability of HDL-C to promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion HDL-C 13,14. Anti-atherogenic properties may be independent of their involvement in cholesterol homeostasis. In this regard, HDL-C may also have role in modulating immune system and other potent biological activities, including antioxidative, anti-inflammatory, anti-infectious and vasodilatory actions. Moreover, it improves endothelial function, promote endothelial repair and increase insulin sensitivity 15-17.
Benefit of increasing HDL-C
The inverse relationship between HDL-C levels and cardiovascular risk led to the development of new therapies that increase HDL-C to decrease cardiovascular disease. Among currently available compounds, statins do not seems to have a sufficient effect on HDL-C profile.
Benefit of increasing HDL-C levels was evaluated by two randomized trials and multivariate analyses that in which the primary target was lowering LDL-C. VA-HIT trial designed evaluate effect of rising HDL for secondary prevention of CHD: 2531 patients with CHD who had an LDL-cholesterol ≤140 mg/dL, HDL-cholesterol ≤40 mg/dL, and triglycerides ≤300 mg/dL were included. They were randomly assigned to treatment with gemfibrozil or placebo 18. After one year, the following differences were seen in the gemfibrozil group: mean HDL-cholesterol level was 6 percent higher, the mean total cholesterol and mean triglyceride concentration was lower (4 and 31 percent respectively). These differences persisted throughout the study. At five years, the combined primary end point of cardio-vascular death and nonfatal myocardial infarction seen less often in the gemfibrozil using group. Patients using gemfibrozil also had a lower rate of stroke 
Causes of low plasma HDL-cholesterol
The causes of low HDL-C include rare genetic disorders 22), familial hypoalphalipoproteinemia 
Cholesteryl ester transfer protein (CETP) inhibitors
It has been shown that torcetrapib, anacetrapib, and dalcetrapib inhibit CETP and increase the HDL-cholesterol levels 35-37. However, trail with torcetrapib has stopped due to unexpected pharmacological effects that led to an increased risk of cardiovascular events and deaths.
Anacetrapib and dalcetrapib, which differ in their mechanism of action from torcetrapib, are under investigation 38,40. The ultimate effect of CETP inhibition on cardiovascular disease outcomes remains to be determined
Therapies that under investigations
The It is well established that reducing LDL-C levels using statins can significantly reduce CV risks 43. However, even in patients who fully attain their recommended LDL-C target, residual CV risks remains high (~65%). Because, low level of HDL-C also an independent risk factor for CVD and the low HDL-C is often present in high-risk CVD patients 44.
Future strategies to reduce residual CV risk should therefore include increasing HDL-C levels in addition to lowering levels of atherogenic lipoproteins. In these regards promising agents like apo-AI analogs and new CETP inhibitors have opened new expectations for the treatment. 
